Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells $2,546,100.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $169.74, for a total value of $2,546,100.00. Following the sale, the chief executive officer owned 551,683 shares in the company, valued at approximately $93,642,672.42. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The shares were sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Stock Up 4.2%

GILD opened at $174.48 on Thursday. The company has a market capitalization of $216.41 billion, a P/E ratio of -55.22 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. The firm’s fifty day moving average price is $152.29 and its two-hundred day moving average price is $140.52. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $175.65.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the prior year, the company posted $2.47 EPS. The business’s revenue was up 6.8% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post -1.07 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. Gilead Sciences’s payout ratio is presently -103.80%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on GILD shares. Barclays cut their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Wells Fargo & Company upped their price objective on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. HSBC upped their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Sanford C. Bernstein reissued an “outperform” rating and issued a $175.00 target price on shares of Gilead Sciences in a report on Monday. Finally, Jefferies Financial Group set a $196.00 target price on Gilead Sciences in a research report on Wednesday. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $170.15.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $15,393,785,000. State Street Corp raised its stake in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after acquiring an additional 1,357,967 shares during the last quarter. Amundi boosted its holdings in shares of Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $918,387,000. Institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.